ml-3000 has been researched along with rupatadine in 1 studies
| Studies (ml-3000) | Trials (ml-3000) | Recent Studies (post-2010) (ml-3000) | Studies (rupatadine) | Trials (rupatadine) | Recent Studies (post-2010) (rupatadine) |
|---|---|---|---|---|---|
| 130 | 9 | 56 | 116 | 43 | 62 |
| Protein | Taxonomy | ml-3000 (IC50) | rupatadine (IC50) |
|---|---|---|---|
| Platelet-activating factor receptor | Homo sapiens (human) | 3.7 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0039 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
1 review(s) available for ml-3000 and rupatadine
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |